CH-01 is a hypoxia-activated prodrug that sensitizes cells to hypoxia/reoxygenation through inhibition of Chk1 and aurora A

ACS Chemical Biology

Volumn 8, Issue 7, 2013, Pages 1451-1459

  Cazares Körner, Cindy ^a,b   Pires, Isabel M ^a   Swallow, I Diane ^b   Grayer, Samuel C ^b   O'Connor, Liam J ^a,b   Olcina, Monica M ^a   Christlieb, Martin ^a   Conway, Stuart J ^b   Hammond, Ester M ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CH 01; PRODRUG; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CELL SURVIVAL; CELL VIABILITY; CLONOGENIC ASSAY; CONTROLLED STUDY; DNA DAMAGE; DNA REPLICATION; DRUG MECHANISM; DRUG SYNTHESIS; ELECTRON; HUMAN; HUMAN CELL; HYPOXIA; PRIORITY JOURNAL; REOXYGENATION; STRUCTURE ACTIVITY RELATION;

AURORA KINASE A; CELL HYPOXIA; CELL LINE, TUMOR; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG DELIVERY SYSTEMS; ENZYME ACTIVATION; ENZYME INHIBITORS; FLUORESCENT ANTIBODY TECHNIQUE; FURANS; HUMANS; MOLECULAR STRUCTURE; OXIDATION-REDUCTION; PRODRUGS; PROTEIN KINASES; PYRIMIDINES;

EID: 84880523069     PISSN: 15548929     EISSN: 15548937     Source Type: Journal    
DOI: 10.1021/cb4001537     Document Type: Article

References (47)

1. Halazonetis, T. D., Gorgoulis, V. G., and Bartek, J. (2008) An oncogene-induced DNA damage model for cancer development Science 319, 1352-1355
2. Chen, T., Stephens, P. A., Middleton, F. K., and Curtin, N. J. (2012) Targeting the S and G2 checkpoint to treat cancer Drug Discovery Today 17, 194-202
3. Murga, M., Campaner, S., Lopez-Contreras, A. J., Toledo, L. I., Soria, R., Montana, M. F., D'Artista, L., Schleker, T., Guerra, C., Garcia, E., Barbacid, M., Hidalgo, M., Amati, B., and Fernandez-Capetillo, O. (2011) Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors Nat. Struct. Mol. Biol. 18, 1331-1335
4. Gilad, O., Nabet, B. Y., Ragland, R. L., Schoppy, D. W., Smith, K. D., Durham, A. C., and Brown, E. J. (2010) Combining ATR suppression with oncogenic Ras synergistically increases genomic instability, causing synthetic lethality or tumorigenesis in a dosage-dependent manner Cancer Res. 70, 9693-9702
5. Cole, K. A., Huggins, J., Laquaglia, M., Hulderman, C. E., Russell, M. R., Bosse, K., Diskin, S. J., Attiyeh, E. F., Sennett, R., Norris, G., Laudenslager, M., Wood, A. C., Mayes, P. A., Jagannathan, J., Winter, C., Mosse, Y. P., and Maris, J. M. (2011) RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma Proc. Natl. Acad. Sci. U.S.A. 108, 3336-3341
6. Hoglund, A., Nilsson, L. M., Muralidharan, S. V., Hasvold, L. A., Merta, P., Rudelius, M., Nikolova, V., Keller, U., and Nilsson, J. A. (2011) Therapeutic implications for the induced levels of Chk1 in Myc-expressing cancer cells Clin. Cancer Res. 17, 7067-7079
7. Ferrao, P. T., Bukczynska, E. P., Johnstone, R. W., and McArthur, G. A. (2011) Efficacy of CHK inhibitors as single agents in MYC-driven lymphoma cells Oncogene 31, 1661-1672
8. Cavelier, C., Didier, C., Prade, N., Mansat-De Mas, V., Manenti, S., Recher, C., Demur, C., and Ducommun, B. (2009) Constitutive activation of the DNA damage signaling pathway in acute myeloid leukemia with complex karyotype: potential importance for checkpoint targeting therapy Cancer Res. 69, 8652-8661
9. Pires, I. M., Olcina, M. M., Anbalagan, S., Pollard, J. R., Reaper, P. M., Charlton, P. A., McKenna, W. G., and Hammond, E. M. (2012) Targeting radiation-resistant hypoxic tumour cells through ATR inhibition Br. J. Cancer 107, 291-299
10. Peasland, A., Wang, L. Z., Rowling, E., Kyle, S., Chen, T., Hopkins, A., Cliby, W. A., Sarkaria, J., Beale, G., Edmondson, R. J., and Curtin, N. J. (2011) Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines Br. J. Cancer 105, 372-381
11. Toledo, L. I., Murga, M., Zur, R., Soria, R., Rodriguez, A., Martinez, S., Oyarzabal, J., Pastor, J., Bischoff, J. R., and Fernandez-Capetillo, O. (2011) A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations Nat. Struct. Mol. Biol. 18, 721-727
12. Ma, C. X., Janetka, J. W., and Piwnica-Worms, H. (2011) Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics Trends Mol. Med. 17, 88-96
13. Reaper, P. M., Griffiths, M. R., Long, J. M., Charrier, J. D., Maccormick, S., Charlton, P. A., Golec, J. M., and Pollard, J. R. (2011) Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR Nat. Chem. Biol. 7, 428-430
14. Prevo, R., Fokas, E., Reaper, P. M., Charlton, P. A., Pollard, J. R., McKenna, W. G., Muschel, R. J., and Brunner, T. B. (2012) The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy Cancer Biol. Ther. 13, 1072-1081
15. Blasina, A., Hallin, J., Chen, E., Arango, M. E., Kraynov, E., Register, J., Grant, S., Ninkovic, S., Chen, P., Nichols, T., O'Connor, P., and Anderes, K. (2008) Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1 Mol. Cancer Ther. 7, 2394-2404
16. Janetka, J. W., Ashwell, S., Zabludoff, S., and Lyne, P. (2007) Inhibitors of checkpoint kinases: from discovery to the clinic Curr. Opin. Drug Discovery Devel 10, 473-486
17. Syljuasen, R. G., Sorensen, C. S., Hansen, L. T., Fugger, K., Lundin, C., Johansson, F., Helleday, T., Sehested, M., Lukas, J., and Bartek, J. (2005) Inhibition of human Chk1 causes increased initiation of DNA replication, phosphorylation of ATR targets, and DNA breakage Mol. Cell. Biol. 25, 3553-3562
18. Carrassa, L. and Damia, G. (2011) Unleashing Chk1 in cancer therapy Cell Cycle 10, 2121-2128
19. Vaupel, P. and Hockel, M. (2003) Tumor oxygenation and its relevance to tumor physiology and treatment Adv. Exp. Med. Biol. 510, 45-49
20. Brown, J. M. and Giaccia, A. J. (1998) The unique physiology of solid tumors: opportunities (and problems) for cancer therapy Cancer Res. 58, 1408-1416
21. Bencokova, Z., Kaufmann, M. R., Pires, I. M., Lecane, P. S., Giaccia, A. J., and Hammond, E. M. (2009) ATM activation and signaling under hypoxic conditions Mol. Cell. Biol. 29, 526-537
22. Olcina, M., Lecane, P. S., and Hammond, E. M. (2010) Targeting hypoxic cells through the DNA damage response Clin. Cancer Res. 16, 5624-5629
23. Pires, I. M., Bencokova, Z., Milani, M., Folkes, L. K., Li, J. L., Stratford, M. R., Harris, A. L., and Hammond, E. M. (2010) Effects of acute versus chronic hypoxia on DNA damage responses and genomic instability Cancer Res. 70, 925-935
24. Wilson, W. R. and Hay, M. P. (2011) Targeting hypoxia in cancer therapy Nat. Rev. Cancer 11, 393-410
25. Evans, J. W., Chernikova, S. B., Kachnic, L. A., Banath, J. P., Sordet, O., Delahoussaye, Y. M., Treszezamsky, A., Chon, B. H., Feng, Z., Gu, Y., Wilson, W. R., Pommier, Y., Olive, P. L., Powell, S. N., and Brown, J. M. (2008) Homologous recombination is the principal pathway for the repair of DNA damage induced by tirapazamine in mammalian cells Cancer Res. 68, 257-265
26. Albertella, M. R., Loadman, P. M., Jones, P. H., Phillips, R. M., Rampling, R., Burnet, N., Alcock, C., Anthoney, A., Vjaters, E., Dunk, C. R., Harris, P. A., Wong, A., Lalani, A. S., and Twelves, C. J. (2008) Hypoxia-selective targeting by the bioreductive prodrug AQ4N in patients with solid tumors: results of a phase I study Clin. Cancer Res. 14, 1096-1104
27. Jameson, M. B., Rischin, D., Pegram, M., Gutheil, J., Patterson, A. V., Denny, W. A., and Wilson, W. R. (2010) A phase I trial of PR-104, a nitrogen mustard prodrug activated by both hypoxia and aldo-keto reductase 1C3, in patients with solid tumors Cancer Chemother. Pharmacol. 65, 791-801
28. Wang, J., Foehrenbacher, A., Su, J., Patel, R., Hay, M. P., Hicks, K. O., and Wilson, W. R. (2012) The 2-nitroimidazole EF5 is a biomarker for oxidoreductases that activate the bioreductive prodrug CEN-209 under hypoxia Clin. Cancer Res. 18, 1684-1695
29. Rischin, D., Peters, L. J., O'Sullivan, B., Giralt, J., Fisher, R., Yuen, K., Trotti, A., Bernier, J., Bourhis, J., Ringash, J., Henke, M., and Kenny, L. (2010) Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group J. Clin. Oncol. 28, 2989-2995
30. Peters, L. J., O'Sullivan, B., Giralt, J., Fitzgerald, T. J., Trotti, A., Bernier, J., Bourhis, J., Yuen, K., Fisher, R., and Rischin, D. (2010) Critical impact of radiotherapy protocol compliance and quality in the treatment of advanced head and neck cancer: results from TROG 02.02 J. Clin. Oncol. 28, 2996-3001
31. Hunter, F. W., Wang, J., Patel, R., Hsu, H. L., Hickey, A. J., Hay, M. P., and Wilson, W. R. (2012) Homologous recombination repair-dependent cytotoxicity of the benzotriazine di-N-oxide CEN-209: comparison with other hypoxia-activated prodrugs Biochem. Pharmacol. 83, 574-585
32. Sun, J. D., Liu, Q., Wang, J., Ahluwalia, D., Ferraro, D., Wang, Y., Duan, J. X., Ammons, W. S., Curd, J. G., Matteucci, M. D., and Hart, C. P. (2012) Selective tumor hypoxia targeting by hypoxia-activated prodrug TH-302 inhibits tumor growth in preclinical models of cancer Clin. Cancer Res. 18, 758-770
33. Zhang, Z., Tanabe, K., Hatta, H., and Nishimoto, S. (2005) Bioreduction activated prodrugs of camptothecin: molecular design, synthesis, activation mechanism and hypoxia selective cytotoxicity Org. Biomol. Chem. 3, 1905-1910
34. Granchi, C., Funaioli, T., Erler, J. T., Giaccia, A. J., Macchia, M., and Minutolo, F. (2009) Bioreductively activated lysyl oxidase inhibitors against hypoxic tumours ChemMedChem 4, 1590-1594
35. Zhu, R., Liu, M. C., Luo, M. Z., Penketh, P. G., Baumann, R. P., Shyam, K., and Sartorelli, A. C. (2011) 4-nitrobenzyloxycarbonyl derivatives of O(6)-benzylguanine as hypoxia-activated prodrug inhibitors of O(6)-alkylguanine-DNA alkyltransferase (AGT), which produces resistance to agents targeting the O-6 position of DNA guanine J. Med. Chem. 54, 7720-7728
36. Hammond, E. M., Dorie, M. J., and Giaccia, A. J. (2004) Inhibition of ATR leads to increased sensitivity to hypoxia/reoxygenation Cancer Res. 64, 6556-6562
37. Pires, I. M., Bencokova, Z., McGurk, C., and Hammond, E. M. (2010) Exposure to acute hypoxia induces a transient DNA damage response which includes Chk1 and TLK1 Cell Cycle 9, 2502-2507
38. Foloppe, N., Fisher, L. M., Howes, R., Kierstan, P., Potter, A., Robertson, A. G., and Surgenor, A. E. (2005) Structure-based design of novel Chk1 inhibitors: insights into hydrogen bonding and protein-ligand affinity J. Med. Chem. 48, 4332-4345
39. Coumar, M. S., Chu, C. Y., Lin, C. W., Shiao, H. Y., Ho, Y. L., Reddy, R., Lin, W. H., Chen, C. H., Peng, Y. H., Leou, J. S., Lien, T. W., Huang, C. T., Fang, M. Y., Wu, S. H., Wu, J. S., Chittimalla, S. K., Song, J. S., Hsu, J. T., Wu, S. Y., Liao, C. C., Chao, Y. S., and Hsieh, H. P. (2010) Fast-forwarding hit to lead: aurora and epidermal growth factor receptor kinase inhibitor lead identification J. Med. Chem. 53, 4980-4988
40. Manchado, E., Guillamot, M., and Malumbres, M. (2012) Killing cells by targeting mitosis Cell Death Differ. 19, 369-377
41. Shigenaga, A., Ogura, K., Hirakawa, H., Yamamoto, J., Ebisuno, K., Miyamoto, L., Ishizawa, K., Tsuchiya, K., and Otaka, A. (2012) Development of a reduction-responsive amino acid that induces peptide bond cleavage in hypoxic cells ChemBioChem 13, 968-971
42. Sorensen, C. S. and Syljuasen, R. G. (2011) Safeguarding genome integrity: the checkpoint kinases ATR, CHK1 and WEE1 restrain CDK activity during normal DNA replication Nucleic Acids Res. 10.1093/nar/gkr697
43. Crosio, C., Fimia, G. M., Loury, R., Kimura, M., Okano, Y., Zhou, H., Sen, S., Allis, C. D., and Sassone-Corsi, P. (2002) Mitotic phosphorylation of histone H3: spatio-temporal regulation by mammalian Aurora kinases Mol. Cell. Biol. 22, 874-885
44. Harrigan, J. A., Belotserkovskaya, R., Coates, J., Dimitrova, D. S., Polo, S. E., Bradshaw, C. R., Fraser, P., and Jackson, S. P. (2011) Replication stress induces 53BP1-containing OPT domains in G1 cells J. Cell Biol. 193, 97-108
45. Buffa, F. M., Harris, A. L., West, C. M., and Miller, C. J. (2010) Large meta-analysis of multiple cancers reveals a common, compact and highly prognostic hypoxia metagene Br. J. Cancer 102, 428-435
46. Moon, E. J., Brizel, D. M., Chi, J. T., and Dewhirst, M. W. (2007) The potential role of intrinsic hypoxia markers as prognostic variables in cancer Antioxid. Redox Signaling 9, 1237-1294
47. Ebbesen, P., Pettersen, E. O., Gorr, T. A., Jobst, G., Williams, K., Kieninger, J., Wenger, R. H., Pastorekova, S., Dubois, L., Lambin, P., Wouters, B. G., Van Den Beucken, T., Supuran, C. T., Poellinger, L., Ratcliffe, P., Kanopka, A., Gorlach, A., Gasmann, M., Harris, A. L., Maxwell, P., and Scozzafava, A. (2009) Taking advantage of tumor cell adaptations to hypoxia for developing new tumor markers and treatment strategies J. Enzyme Inhib. Med. Chem. 24 (Suppl 1) 1-39